Eye diseases

The category eye diseases as defined by the German Federal Joint Committee (G-BA) groups together medicinal products for the treatment of diseases such as macular degeneration, and for the reduction of intraocular pressure, postoperative pain after eye operations, inflammation after cataract operations or vitreomacular traction. So far 14 different medicinal products have been assessed in 25 procedures. A major additional benefit has been demonstrated for 0% of the subpopulations (weighted according to patient share in the resolution). A considerable additional benefit has been found for 11.8% of these subpopulations and a minor additional benefit for 3.8%. A non-quantifiable additional benefit has been demonstrated for 16% of the subpopulations.

By contrast, the G-BA has stated that an additional benefit compared to the appropriate comparative treatment has not been proved for 68.4% of the weighted subpopulations, corresponding to 99% of the theoretical total population of 5.21 million patients for all medicinal products evaluated in this therapeutic area.